Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Alle Spezies anzeigen
Weitere Synonyme anzeigen
Wählen Sie die Spezies und Applikation aus
anti-Human DLC1 Antikörper:
anti-Mouse (Murine) DLC1 Antikörper:
anti-Rat (Rattus) DLC1 Antikörper:
Sie gelangen zu unserer vorgefilterten Suche.
Human Polyclonal DLC1 Primary Antibody für IHC (p), IHC - ABIN268701
Ko, Yeung, Wong, Chan, Poon, Ng, Yam: Deleted in liver cancer 1 isoforms are distinctly expressed in human tissues, functionally different and under differential transcriptional regulation in hepatocellular carcinoma. in Liver international : official journal of the International Association for the Study of the Liver 2009
Show all 2 Pubmed References
Human Polyclonal DLC1 Primary Antibody für IHC, IHC (p) - ABIN4305321
Muehlich, Hampl, Khalid, Singer, Frank, Breuhahn, Gudermann, Prywes: The transcriptional coactivators megakaryoblastic leukemia 1/2 mediate the effects of loss of the tumor suppressor deleted in liver cancer 1. in Oncogene 2012
DLC1 (zeige DYNLL1 Antikörper) is the predominant family member expressed in several normal tissues, and its expression is preferentially reduced in common cancers at these sites.
Fluctuation of reactive oxygen species inhibited migration through reducing the interaction between DLC1 (zeige DYNLL1 Antikörper) and CAV-1 (zeige CAV1 Antikörper).
IGF2 may exert its oncofunction, at least partly, through its parasitic miR (zeige MLXIP Antikörper)-483 which suppressed DLC-1 (zeige DYNLL1 Antikörper) in colorectal cancer cells. DLC-1 (zeige DYNLL1 Antikörper) expression was decreased in colorectal cancer tissues and diminished through transient transfection with miR (zeige MLXIP Antikörper)-483-3p.
The results of this study showed for the first time that CpGs of the DLC1 (zeige DYNLL1 Antikörper)-v1 alternative promoter is frequently hypermethylated in tumors of meningeal origin.
Receptor tyrosine kinase (zeige RET Antikörper) activation of RhoA (zeige RHOA Antikörper) is mediated by AKT (zeige AKT1 Antikörper) phosphorylation of DLC1 (zeige DYNLL1 Antikörper).
Study suggests a mechanism for EZH2 (zeige EZH2 Antikörper)-H3K27me3 epigenetic repression of DLC1 (zeige DYNLL1 Antikörper) and multilayered regulation of DLC1 (zeige DYNLL1 Antikörper)/Rho/ROCK signaling by EZH2 (zeige EZH2 Antikörper), and advocated the significant pro-metastatic role of EZH2 (zeige EZH2 Antikörper) via repressing tumor and metastasis suppressors.
The results identify DLC1 (zeige DYNLL1 Antikörper) as an activator of white and brown adipocyte differentiation, and provide a molecular link between PPARgamma (zeige PPARG Antikörper) and Rho pathways.
DLC-1 (zeige DYNLL1 Antikörper) has a positive regulatory role in endothelial cell angiogenesis.
Subsequent studies have demonstrated that DLC-1 (zeige DYNLL1 Antikörper) is generally expressed in normal human tissues as well as in rats, while it always exists inactivated or even lost in many human cancers, which characterizes DLC-1 (zeige DYNLL1 Antikörper) as a potential tumor suppressor. [review]
Tumor suppressor genes deleted in liver cancer 1 (DLC1), F-box/WD-repeat-containing protein 7 (FBXW7 (zeige FBXW7 Antikörper)), and cadherin-6 (CDH6 (zeige CDH6 Antikörper)) were identified as presumed targets in Cholangiocarcinoma (CC).Inverse correlation between promoter methylation and expression suggested miR (zeige MLXIP Antikörper)-129-2 and members of the miR (zeige MLXIP Antikörper)-200 family (miR (zeige MLXIP Antikörper)-200a, miR (zeige MLXIP Antikörper)-200b, and miR (zeige MLXIP Antikörper)-429) as novel tumor suppressors and oncomiRs, respectively, in CC
DLC-1 has a positive regulatory role in endothelial cell angiogenesis.
studies demonstrate that TNS1 (zeige TNS1 Antikörper) binds to DLC1 and fine-tunes its RhoGAP (zeige ARHGAP1 Antikörper) activity toward RhoA (zeige RHOA Antikörper) and that the TNS1 (zeige TNS1 Antikörper)-DLC1-RhoA (zeige RHOA Antikörper) signaling axis is critical in regulating cellular functions that lead to angiogenesis
Loss of expression of only Dlc1 isoform 2 may be sufficient for the development of thymic tumors and metastasis.
Several genes and biochemical activities collaborate with the inactivation of DLC1 to give rise to cell transformation in MEFs, and the identified genes are relevant to human tumors with low DLC1 expression.
The Dlc1 deficient cells showed altered cytoskeleton structure, increased RhoA (zeige RHOA Antikörper) activity and cellular migration.
DLC-1-/- embryos had defects in the neural tube, brain, heart, and placenta
Our data validate DLC1 as a potent tumor suppressor gene and suggest that its loss creates a dependence on the RhoA (zeige RHOA Antikörper) pathway that may be targeted therapeutically.
This gene encodes a GTPase-activating protein (GAP) that is a member of the rhoGAP family of proteins which play a role in the regulation of small GTP-binding proteins. GAP family proteins participate in signaling pathways that regulate cell processes involved in cytoskeletal changes. This gene functions as a tumor suppressor gene in a number of common cancers, including prostate, lung, colorectal, and breast cancers. Multiple transcript variants due to alternative promoters and alternative splicing have been found for this gene.
Rho-GTPase-activating protein 7
, START domain-containing protein 12
, StAR-related lipid transfer (START) domain containing 12
, deleted in liver cancer 1 protein
, deleted in liver cancer 1 variant 2
, rho GTPase-activating protein 7
, rho-type GTPase-activating protein 7
, deleted in liver cancer 1
, deleted in liver cancer 1 protein homolog
, stAR-related lipid transfer protein 12
, rho GTPase-activating protein 7-like
, Deleted in liver cancer 1 protein homolog
, Rho-type GTPase-activating protein 7
, rho GTPase activating protein 7